Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News NetworkPRNewsWire • 08/12/22
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 DataPRNewsWire • 07/26/22
Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial DataPRNewsWire • 07/20/22
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease TrialPRNewsWire • 04/19/22
New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's DiseasePRNewsWire • 04/05/22
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development SummitPRNewsWire • 03/29/22
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)PRNewsWire • 03/15/22
Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple SclerosisPRNewsWire • 02/23/22
Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease PatientsPRNewsWire • 02/01/22
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease TreatmentSeeking Alpha • 11/17/21
5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin LeaderboardBenzinga • 11/15/21
Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological DiseasesBenzinga • 10/05/21
Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/10/21
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X SyndromePRNewsWire • 08/05/21
Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021PRNewsWire • 07/26/21
Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above BaselinePRNewsWire • 07/14/21